Company news

Myriad Genetics, Inc. news in 2023

Myriad Genetics, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Myriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial Guidance

December 20, 2023

Myriad Genetics Establishes Comprehensive Pan-Cancer Research Platform to Advance Patient Care

December 19, 2023

Myriad Genetics Celebrates One Million SneakPeek® Results Shared with Expectant Parents

November 19, 2023

Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers

November 15, 2023

Myriad Genetics to Participate in Stephens Annual Investment Conference

November 8, 2023

Myriad Genetics Announces Proposed Offering of $100 Million of Shares of Common Stock

November 7, 2023

Myriad Genetics Announces Pricing of Upsized Offering of Common Stock

November 7, 2023

Myriad Genetics Reports Third Quarter 2023 Financial Results; Generates Double-Digit Revenue Growth; Raises 2023 Revenue Guidance and Introduces 2024 Revenue Guidance

November 5, 2023

Myriad Genetics Appoints Sam Raha as Chief Operating Officer

October 31, 2023

Myriad Genetics to Release Third Quarter Financial Results on November 6, 2023

October 30, 2023

QIAGEN and Myriad Genetics partner to advance companion diagnostics development for cancer

October 25, 2023

New Myriad Genetics Survey Shows Breast Cancer Risk Factors Are Misunderstood

September 27, 2023

Breast cancer awareness month: new cancer risk survey reveals risk factors are widely misunderstood

September 27, 2023

Myriad Genetics Issues 2022 Environmental, Social and Governance Report

September 18, 2023

Myriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials

September 18, 2023

Myriad Genetics and Leading Cancer Center Collaborate to Study the Use of Minimal Residual Disease Testing in Breast Cancer

September 17, 2023

New Myriad Genetics Survey Reveals Widespread Confusion and Misconceptions About Ovarian Cancer Screening Among a Majority of Women

September 5, 2023

Myriad Genetics Named to 2023 Best Workplaces in Health Care List by Fortune and Great Place To Work

September 5, 2023

Myriad Genetics to Participate in Morgan Stanley Global Healthcare Conference

September 4, 2023

Myriad Genetics and Onsite Women’s Health Partner to Help More Women Understand Breast Cancer Risk

August 21, 2023

Myriad Genetics to Host Investor Day on September 19, 2023

August 16, 2023

Myriad Genetics Advances Prostate Cancer Care with Addition of Absolute Risk Reduction to Prolaris®

August 14, 2023

Myriad Genetics and Intermountain Health Participate in ComboMATCH, a National Clinical Trial to Advance Cancer Treatment

August 7, 2023

Myriad Genetics Announces Enhancements to the GeneSight® Test to Personalize Mental Health Medication Treatment Decisions Based on Smoking Status

August 6, 2023

Myriad Genetics Reports Second Quarter 2023 Financial Results and Reaffirms 2023 Revenue and Adjusted EPS Guidance; Generates the Fourth Consecutive Quarter of Double-Digit Year-Over-Year Testing Volume Growth

August 2, 2023

Myriad Genetics to Release Second Quarter Financial Results on Aug. 3, 2023

July 26, 2023

Myriad Genetics Announces Inclusion of Breast Density to MyRisk® with RiskScore® Breast Cancer Risk Assessment

July 23, 2023

Myriad Genetics Announces New $90 Million Asset-Based Credit Facility

July 5, 2023

Myriad Genetics Announces Research Collaboration to use Minimal Residual Disease Testing Platform

June 11, 2023

Myriad Genetics to Participate in Goldman Sachs Healthcare Conference

June 6, 2023

Myriad Genetics Highlights Latest Oncology Portfolio Advancements and New Data at ASCO 2023

May 31, 2023

Adam Brufsky, MD, PhD, FACP Named Oncology Scientific Advisor to Myriad Genetics

May 30, 2023

Myriad Genetics Adds Folate Receptor Alpha to Precise™ Oncology Solutions Portfolio to Expand Treatment Options for Women Living with Ovarian Cancer

May 23, 2023

Myriad Genetics Earns 2023 Great Place to Work Certification™

May 7, 2023

Myriad Genetics Reports First Quarter 2023 Financial Results; Achieves 10% Revenue Growth Year-Over-Year, the Second Consecutive Quarter of Double-Digit Year-Over-Year Revenue Growth; Raises Mid-Point of 2023 Revenue Guidance Range

May 2, 2023

Myriad Genetics to Participate in BofA Securities Healthcare Conference

May 1, 2023

Myriad Genetics to Release First Quarter Financial Results on May 3, 2023

April 25, 2023

77% of Americans have used addictive behaviors or unhealthy coping mechanisms to manage their mental health, according to Myriad Genetics nationwide survey

April 18, 2023

Myriad Genetics and Intermountain Precision Genomics Now Offer Solid Tumor Testing in All 50 States with Latest NY State Certification

April 17, 2023

Myriad Genetics and SimonMed® Imaging Collaborate to Advance Precision Medicine with New Genetic Risk Assessment Program

April 11, 2023

Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States

March 1, 2023

Myriad Genetics Applauds New Expanded Carrier Screening Practice Guidelines from NSGC

February 28, 2023

Myriad Genetics Reports Fourth Quarter Financial Results; Fourth Quarter Revenue of $177.8 Million Grew 11% Year-Over-Year Driven by 16% Growth in Hereditary Cancer Volumes and 23% Growth in GeneSight® Volumes

February 27, 2023

Myriad Genetics to Release Fourth-Quarter Financial Results on Feb. 28, 2023

February 21, 2023

Myriad Genetics to Participate in Upcoming Healthcare Conferences

February 8, 2023

Myriad Genetics Highlights 2022 Research Findings that Help Advance More Accessible and Equitable Genetic Testing

February 6, 2023

Myriad Genetics Applauds New Guidelines Recommending Screening for Chromosomal Abnormalities

January 4, 2023

Myriad Genetics to Present at 41st Annual J.P. Morgan Healthcare Conference

January 3, 2023

Calls in 2023

Decks in 2023